Natixis Advisors LLC Boosts Stock Position in Repligen Co. (NASDAQ:RGEN)

Natixis Advisors LLC raised its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 31.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,317 shares of the biotechnology company's stock after purchasing an additional 10,692 shares during the period. Natixis Advisors LLC owned 0.08% of Repligen worth $6,379,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Champlain Investment Partners LLC lifted its holdings in shares of Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after buying an additional 850,345 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Repligen in the 4th quarter valued at $52,492,000. Allspring Global Investments Holdings LLC grew its position in Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock worth $65,395,000 after purchasing an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. increased its holdings in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after purchasing an additional 139,615 shares during the period. Finally, Two Sigma Advisers LP raised its position in shares of Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company's stock valued at $18,796,000 after buying an additional 102,100 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. Royal Bank of Canada increased their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. Finally, Evercore ISI started coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $178.64.

Repligen Price Performance

RGEN stock traded down $3.20 during mid-day trading on Tuesday, reaching $141.95. The company's stock had a trading volume of 730,947 shares, compared to its average volume of 651,970. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company's 50 day moving average is $155.62 and its two-hundred day moving average is $148.36. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $187.25. The stock has a market cap of $7.97 billion, a PE ratio of -278.33, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Equities research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.